江苏健安生物科技有限公司(ImmuOn Therapeutics)是由海外归国华人科学家成立，集新药研发、成果转化及生产制造于一体的新一代科技型民营股份企业。为国内领先免疫治疗公司，专注于成人预防性及治疗性疫苗及相关免疫治疗药物研发。
健安生物的主要研发管线包括致癌病毒的预防性和治疗性疫苗，以及基于癌症“新生抗原”的治疗性疫苗。公司开发的独特的EpiVaxTM技术平台通过优化和选择具有强烈抗原性的病毒和肿瘤抗原表位，提高了治疗性疫苗的特异性和多元性的问题，提高疫苗的有效性和广谱型。
公司创业和顾问团队成员均为长期在海外国际医药公司研究各类疫苗二十多年、卓有成就的专家，曾服务于凯伦(Chiron)、默沙东(Merck)、诺华(Novartis)、健赞(Genezyme)等公司。
我们坚信通过与国内外同仁广泛的合作和努力，免疫治疗将迎来一个全盛的时代。
ImmuOn Therapeutics is founded by achieved scientists in vaccine research who had worked before for major international pharmaceutical companies such as AstraZeneca, Chiron、Merck, Novartis, and Genezyme.
ImmuOn is the pioneer and leading immunotherapy research and development company in China and is a fully integrated biotech company.
The major research and development pipeline of ImmuOn includes preventive and therapeutic vaccines against oncoviruses and neoantigen based cancer therapeutic vaccines . Our proprietary technology platform “EpiVaxTM” allows fast and effective screening and selection of strong immunogenic epitopes from viral and tumor antigens and hence improve the specificity and effectivenes of therapeutic vaccines, as well as broad coverage of multi-antigens in a single vaccine .
We believe the immunotherapy will enter a fruitful new era through international collaboration.
